1. Home
  2. TNET vs ABCL Comparison

TNET vs ABCL Comparison

Compare TNET & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TriNet Group Inc.

TNET

TriNet Group Inc.

HOLD

Current Price

$69.25

Market Cap

3.0B

ML Signal

HOLD

Logo AbCellera Biologics Inc.

ABCL

AbCellera Biologics Inc.

HOLD

Current Price

$11.41

Market Cap

3.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TNET
ABCL
Founded
1988
2012
Country
United States
Canada
Employees
2700
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.0B
3.5B
IPO Year
2000
2020

Fundamental Metrics

Financial Performance
Metric
TNET
ABCL
Price
$69.25
$11.41
Analyst Decision
Hold
Strong Buy
Analyst Count
5
5
Target Price
$65.80
$8.40
AVG Volume (30 Days)
299.0K
5.2M
Earning Date
04-30-2026
05-11-2026
Dividend Yield
2.57%
N/A
EPS Growth
N/A
10.91
EPS
3.05
N/A
Revenue
$5,010,000,000.00
$75,128,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$3.30
$21.85
P/E Ratio
$21.64
N/A
Revenue Growth
N/A
160.56
52 Week Low
$33.67
$2.75
52 Week High
$73.08
$12.58

Technical Indicators

Market Signals
Indicator
TNET
ABCL
Relative Strength Index (RSI) 54.36 56.96
Support Level $64.80 $10.44
Resistance Level $72.19 $12.58
Average True Range (ATR) 2.28 0.65
MACD -0.57 -0.27
Stochastic Oscillator 57.92 37.61

Price Performance

Historical Comparison
TNET
ABCL

About TNET TriNet Group Inc.

Trinet Group Inc provides human resources solutions for small and medium-sized businesses through technology-enabled services. Its offerings include human capital expertise, employee benefits such as health insurance and retirement plans, payroll and payroll tax administration, risk mitigation, and compliance consulting. The company provides its services through professional employer organization (PEO) services delivered via a co-employment model, as well as administrative services organization (ASO) offerings. The majority of the company's revenue is derived from the insurance-related billings and administrative fees collected from PEO clients.

About ABCL AbCellera Biologics Inc.

AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.

Share on Social Networks: